Fundamental Analysis of VIRIOS THERAPEUTICS INC(NASDAQ:VIRI) stock

Fundamental Rating

Taking everything into account, VIRI scores 2 out of 10 in our fundamental rating. VIRI was compared to 588 industry peers in the Biotechnology industry. VIRI has a great financial health rating, but its profitability evaluates not so good. VIRI is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

VIRI had negative earnings in the past year.

In the past year VIRI has reported a negative cash flow from operations.

VIRI had negative earnings in each of the past 5 years.

In the past 5 years VIRI always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -118.79%, VIRI is doing worse than 83.25% of the companies in the same industry.

With a Return On Equity value of -130.94%, VIRI is not doing good in the industry: 61.54% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-118.79%
ROE	-130.94%
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

VIRI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

VIRI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

VIRI has an Altman-Z score of -8.37. This is a bad value and indicates that VIRI is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -8.37, VIRI is doing worse than 73.50% of the companies in the same industry.

VIRI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-8.37

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 10.77 indicates that VIRI has no problem at all paying its short term obligations.

The Current ratio of VIRI (10.77) is better than 82.56% of its industry peers.

VIRI has a Quick Ratio of 10.77. This indicates that VIRI is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of VIRI (10.77) is better than 82.56% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	10.77
Quick Ratio	10.77

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 81.03% over the past year.

EPS 1Y (TTM)81.03%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q78.57%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

VIRI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.70% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y1.64%

EPS Next 2Y-4.54%

EPS Next 3Y-21.31%

EPS Next 5Y12.7%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

VIRI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year VIRI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as VIRI's earnings are expected to decrease with -21.31% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-4.54%

EPS Next 3Y-21.31%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for VIRI!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VIRIOS THERAPEUTICS INC

NASDAQ:VIRI (4/19/2024, 7:22:42 PM)

After market: 0.4201 -0.02 (-3.54%)

0.4355

-0.01 (-3.2%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap8.39M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-118.79%
ROE	-130.94%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	10.77
Quick Ratio	10.77
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)81.03%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y1.64%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

VIRIOS THERAPEUTICS INC (VIRI)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens